Kriya Therapeutics, Inc., a groundbreaking biopharmaceutical company, just clinched a major victory in its efforts to bring disruptive gene therapies to the world. After raising over $600 million —including a now-closed Series C Financing totaling $430 million —Kriya now has a cash runway extending well into 2026. This massive influx of resources will be instrumental in advancing the company’s expanding pipeline of gene therapies and scaling its suite of engineering, computing, and manufacturing capabilities.
Kriya is revolutionizing healthcare with its groundbreaking gene therapies targeting ophthalmology, neurology and metabolic disorder. Our therapeutic portfolio targets the diseases that have the most unmet medical needs and valid biological targets and clearly defined clinical endpoints, fast-tracking research development to achieve proof-of-concept. We are determined to be at the forefront of developing life-changing treatments for those who need them the most.
Kriya is on a mission to advance gene therapies to highly prevalent diseases that affect millions of people around the world. To make gene therapies a pillar of mainstream medicine, we have built an integrated engine to overcome underlying challenges that have limited gene therapy research, development, and manufacturing.
We are proudly investing in world-class infrastructure and talent to expedite our engineering and production of gene therapies. We are thrilled to harness this momentum for our programs’ translation into the clinic, and to hopefully serve those desperately in need of better treatment options.
“We are thrilled by the potential of gene therapy to open a new horizon of medicine,” said Jim Momtazee, Managing Partner of Patient Square Capital, who led the Series C financing. “At Kriya, we are passionate about broadening the reach of gene therapies, destined to revolutionize the way medical treatment is administered .”
About Kriya Therapeutics
At Kriya, we are on a mission to revolutionize medicine and ultimately eliminate human suffering. We are creating gene therapies that have the potential to make a world without disease a reality. Our operations are located in Palo Alto, California and Research Triangle Park, North Carolina, allowing us to develop treatments for ophthalmology, neurology, and metabolic disease, all of which have raised over $600 million in funding.
We are committed to not only making these treatments available for millions of people worldwide, but to also ensuring that it is done with the utmost care and compassion.